Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer

Case Reports in Oncology

Volumn 7, Issue 3, 2014, Pages 648-655

  Kunzmann, Volker ^a   Herrmann, Ken ^a   Bluemel, Christina ^a   Kapp, Markus ^a   Hartlapp, Ingo ^a   Steger, Ulrich ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

5 Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Locally advanced disease; Nab paclitaxel; Neoadjuvant chemotherapy; Oxaliplatin; Pancreatic cancer

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; ARTICLE; BILE DUCT BYPASS; BILIARY TRACT DRAINAGE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CASE REPORT; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; FROZEN SECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LAPAROTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MICROMETASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREATICOJEJUNOSTOMY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; TREATMENT OUTCOME;

EID: 84927132764     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000367966     Document Type: Article

References (13)

1. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-Analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
2. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
3. Von Hoff DD, Ervin T, Arena F, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.
4. Goldstein D, El-Maraghi RH, Hammel P, et al: Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC) (abstract 4027). J Clin Oncol 2014;32(suppl):5s.
5. Abraxane® prescribing information, October 2013. http://abraxane.com/.
6. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
7. Von Hoff DD, Ervin TJ, Arena FP, et al: Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates (abstract 4005). J Clin Oncol 2013;31(suppl).
8. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B: Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011;11:123.
9. Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M: Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev 2014;40:118-128.
10. Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-4554.
11. Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE: Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis 2013;34:2361-2369.
12. Alvarez R, Musteanu M, Garcia-Garcia E, et al: Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013;109:926-933.
13. Hidalgo M, Plaza C, Illei PB, et al: SPARC analysis in the phase III MPACT trial of nab-paclitaxel plus gemcitabine vs. Gem alone for patients with metastatic pancreatic cancer (abstract O-0004). 16th World Congress on Gastrointestinal Cancer, Barcelona, 2014.